Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 118
Filtrar
2.
Anticancer Res ; 40(7): 3793-3799, 2020 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-32620618

RESUMO

BACKGROUND/AIM: Head and neck squamous cell carcinoma (HNSCC) is one of the most common types of cancer worldwide. Our study focused on the axon guidance receptor roundabout guidance receptor 1 (ROBO1) as a target for monoclonal antibody therapy of HNSCC. We previously showed that saporin-conjugated anti-ROBO1 (B5209B) immunotoxin (IT-ROBO1) enhanced cytotoxic effects on HNSCC cells in combination with the photosensitizer aluminum phthalocyanine disulphonate (AlPcS2a) and illumination. We examined the effects of this combination therapy in a mouse xenograft model. MATERIALS AND METHODS: IT-ROBO1 was intraperitoneally administered to HSQ-89 (derived from Japanese maxillary sinus squamous carcinoma, RCB0789; RIKEN, Tsukuba, Japan) xenografted mice. After 3 days, AlPcS2a was injected subcutaneously around the tumor and the area was illuminated at 650 nm for 30 min. The growth of the tumor was evaluated and the effects on the tumor were examined. RESULTS: Pronounced anti-tumor effects were elicited by the administration of IT-ROBO1 and AlPcS2a with light illumination on tumor size and pathological characteristics. CONCLUSION: The results showed that photosensitizer treatment with illumination robustly enhanced the antitumor effect of the IT-ROBO1 immunotoxin.


Assuntos
Neoplasias de Cabeça e Pescoço/tratamento farmacológico , Imunotoxinas/metabolismo , Seio Maxilar/efeitos dos fármacos , Proteínas do Tecido Nervoso/metabolismo , Fármacos Fotossensibilizantes/farmacologia , Receptores Imunológicos/metabolismo , Carcinoma de Células Escamosas de Cabeça e Pescoço/tratamento farmacológico , Animais , Anticorpos Monoclonais/farmacologia , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Humanos , Masculino , Seio Maxilar/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Carcinoma de Células Escamosas de Cabeça e Pescoço/metabolismo , Ensaios Antitumorais Modelo de Xenoenxerto
3.
J Mater Sci Mater Med ; 30(9): 97, 2019 Aug 22.
Artigo em Inglês | MEDLINE | ID: mdl-31440845

RESUMO

Sinus elevation is a common procedure to increase bone volume in the atrophic maxilla to allow placement of dental implants. Autogenous bone is the gold standard but is limited in quantity and causes morbidity at the donor site. ß-TCP is a synthetic biomaterial commonly used in that purpose. It appears to induce a poor inflammatory response. This study aimed to evaluate the degree of edema of the sinus mucosa after sinus lift surgery according to the type of biomaterial. Forty sinuses (20 patients) were included retrospectively and divided into 2 groups according to the biomaterial that was used: synthetic biomaterial (BTCP group), natural bone (BONE group). A control group (CTRL group) was constituted by the non-grafted maxillary sinuses. Twelve measurements per sinus were realized on pre- and post-operative computed tomography and averaged to provide the sinus membrane thickness value (SM.Th). SM.Th was thicker post-operatively in the BTCP and BONE groups in comparison with the CTRL group and in comparison with pre-operative measurements. No difference was found post operatively between the BTCP and BONE groups. We found that a synthetic biomaterial (ß-TCP) induced the same degree of edema, and thus of inflammation, as natural bone. It constitutes therefore an interesting alternative to autogenous bone for maxillary sinus lifts.


Assuntos
Substitutos Ósseos/efeitos adversos , Transplante Ósseo/efeitos adversos , Fosfatos de Cálcio/efeitos adversos , Fosfatos de Cálcio/química , Sinusite Maxilar/etiologia , Levantamento do Assoalho do Seio Maxilar/efeitos adversos , Adulto , Idoso , Idoso de 80 Anos ou mais , Materiais Biocompatíveis/efeitos adversos , Substitutos Ósseos/química , Transplante Ósseo/métodos , Implantação Dentária Endóssea/efeitos adversos , Implantação Dentária Endóssea/métodos , Implantes Dentários/efeitos adversos , Feminino , Humanos , Inflamação/etiologia , Inflamação/patologia , Masculino , Seio Maxilar/efeitos dos fármacos , Seio Maxilar/patologia , Sinusite Maxilar/patologia , Pessoa de Meia-Idade , Estudos Retrospectivos , Levantamento do Assoalho do Seio Maxilar/métodos
4.
Biomed Res Int ; 2019: 7267062, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31008111

RESUMO

PURPOSE: To date, it remains unknown whether the addition of platelet-rich fibrin (PRF) to bone grafts actually improves the effectiveness of maxillary sinus augmentation. This study aimed to perform a meta-analysis to evaluate the efficacy of PRF in sinus lift. MATERIALS AND METHODS: PubMed, Embase, and the Cochrane Library were searched. Randomized controlled studies were identified. The risk of bias was evaluated using the Cochrane Collaboration tool. RESULTS: Five RCTs were included in our meta-analysis. Clinical, radiographic, and histomorphometric outcomes were considered. No implant failure or graft failure was detected in all included studies within the follow-up period. The percentage of contact length between newly formed bone substitute and bone in the PRF group was lower but lacked statistical significance (3.90%, 95% CI, -2.91% to 10.71%). The percentages of new bone formation (-1.59%, 95% CI, -5.36% to 2.18%) and soft-tissue area (-3.73%, 95% CI, -10.11% to 2.66%) were higher in the PRF group but were not significantly different. The percentage of residual bone graft was not significant in either group (4.57%, 95% CI, 0% to 9.14%). CONCLUSIONS: Within the limitations of this review, it was concluded that there were no statistical differences in survival rate, new bone formation, contact between newly formed bone and bone substitute, percentage of residual bone graft (BSV/TV), and soft-tissue area between the non-PRF and PRF groups. Current evidence supporting the necessity of adding PRF to bone graft in sinus augmentation is limited.


Assuntos
Transplante Ósseo/métodos , Implantação Dentária Endóssea/métodos , Fibrina Rica em Plaquetas , Levantamento do Assoalho do Seio Maxilar , Regeneração Óssea/efeitos dos fármacos , Substitutos Ósseos/farmacologia , Humanos , Seio Maxilar/efeitos dos fármacos , Seio Maxilar/patologia , Ensaios Clínicos Controlados Aleatórios como Assunto
5.
Mater Sci Eng C Mater Biol Appl ; 97: 103-115, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30678894

RESUMO

Injectable bone cement (IBC) such as those based on methacrylates and hydraulic calcium phosphate and calcium sulfate-based cements have been used extensively for filling bone defects with acceptable clinical outcomes. There is a need however for novel IBC materials that can address some of the inherent limitations of currently available formulations to widen the clinical application of IBC. In this study, we characterized a novel hydraulic IBC formulation consisting of bioactive strontium-doped hardystonite (Sr-HT) ceramic microparticles and sodium dihydrogen phosphate, herein named Sr-HT phosphate cement (SPC). The resultant cement is comprised of two distinct amorphous phases with embedded partially reacted crystalline reactants. The novel SPC formulation possesses a unique combination of physicochemical properties suitable for use as an IBC, and demonstrates in vitro cytocompatibility when seeded with primary human osteoblasts. In vivo injection of SPC into rabbit sinus defects show minor new bone formation at the SPC periphery, similar to those exhibited in sinus defects filled with a clinically available calcium phosphate cement. The current SPC formulation presented in this paper shows promise as a clinically applicable IBC which can be further enhanced with additives.


Assuntos
Cimentos Ósseos/química , Cimentos Ósseos/farmacologia , Teste de Materiais/métodos , Silicatos/química , Estrôncio/química , Animais , Osso Esponjoso , Proliferação de Células , Células Cultivadas , Concentração de Íons de Hidrogênio , Injeções , Seio Maxilar/efeitos dos fármacos , Seio Maxilar/fisiologia , Seio Maxilar/cirurgia , Osteoblastos/efeitos dos fármacos , Osteogênese , Fosfatos/química , Coelhos , Difração de Raios X
6.
Oral Maxillofac Surg ; 22(4): 443-450, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-30345483

RESUMO

PURPOSE: Augmentation of the maxillary sinus floor with bone grafting is commonly used for successful treatment of edentulous posterior maxilla with dental implants, and it is essential to maintain good bone volume and quality for long-term success of dental implants. The aim of this experimental study was to investigate the local and systemic effects of boric acid on new bone formation after maxillary sinus floor augmentation (MSFA). MATERIALS AND METHODS: Twenty-four male, New Zealand rabbits were randomly divided into three groups with eight rabbits each, and bilateral MSFA was performed in each animal. An autogenous bone/xenograft mixture was used to augment the maxillary sinuses in each group. Group 1 was determined as control with no additional materials, whereas 3 mg/kg boric acid (BA) was added to the mixture in group 2, and 3 mg/kg boric acid solution added to drinking water daily in group 3. RESULTS: The animals were sacrificed and also histologic, histomorphometric, and immunnohistochemical analyses were performed at weeks 4 and 8. At week 4, bone regeneration was better in the local BA group than in the control and systemic BA groups (p < 0.05). However, no significant difference was found among the groups in terms of bone regeneration at the end of week 8 (p > 0.05). CONCLUSION: Significant higher new bone formation was revealed by BA at early healing especially with local application. BA may be a therapeutic option for improving the bone regeneration.


Assuntos
Ácidos Bóricos/uso terapêutico , Osteogênese/efeitos dos fármacos , Levantamento do Assoalho do Seio Maxilar/métodos , Administração Oral , Animais , Substitutos Ósseos/administração & dosagem , Substitutos Ósseos/uso terapêutico , Transplante Ósseo/métodos , Ácidos Bóricos/administração & dosagem , Masculino , Seio Maxilar/anatomia & histologia , Seio Maxilar/efeitos dos fármacos , Seio Maxilar/cirurgia , Coelhos
7.
Int Forum Allergy Rhinol ; 8(4): 482-489, 2018 04.
Artigo em Inglês | MEDLINE | ID: mdl-29334430

RESUMO

BACKGROUND: The ciprofloxacin-coated sinus stent (CSS) has unique therapeutic potential to deliver antibiotics to the sinuses. The objective of this study is to evaluate the efficacy of the CSS stent in eliminating Pseudomonas aeruginosa infection in a rabbit model of sinusitis. METHODS: A ciprofloxacin-eluting sinus stent was created by coating ciprofloxacin/Eudragit RS100 on biodegradable poly-D/L-lactic acid (2 mg). After analyzing in-vitro inhibition of P aeruginosa (PAO-1 strain) biofilm formation, a total of 8 stents (4 shams, 4 CSSs) were placed unilaterally in rabbit maxillary sinuses via dorsal sinusotomy after inducing infection for 1 week with PAO-1. Animals were assessed 2 weeks after stent insertion with nasal endoscopy, sinus culture, computed tomography (CT) scan, histopathology, and scanning electron microscopy (SEM). RESULTS: PAO-1 biofilm formation was significantly reduced in vitro with exposure to the CSS (p < 0.0001). Insertion of the stent in PAO-1-infected rabbits for 2 weeks resulted in significant improvement in sinusitis according to endoscopy scoring (p < 0.0001) and CT scoring (p < 0.002). Histology and SEM revealed marked improvement in the structure of the mucosa and submucosa with no detection of biofilm structures in the CSS cohort. CONCLUSION: Although this study had a small sample size, we identified robust therapeutic efficacy of the CSS by reducing bacterial load and biofilm formation of P aeruginosa in a preclinical model of sinusitis after placement for 2 weeks.


Assuntos
Antibacterianos/uso terapêutico , Biofilmes/efeitos dos fármacos , Ciprofloxacina/uso terapêutico , Seio Maxilar/efeitos dos fármacos , Mucosa Nasal/patologia , Infecções por Pseudomonas/terapia , Pseudomonas aeruginosa/fisiologia , Sinusite/terapia , Animais , Carga Bacteriana , Biofilmes/crescimento & desenvolvimento , Células Cultivadas , Modelos Animais de Doenças , Stents Farmacológicos , Endoscopia , Humanos , Seio Maxilar/cirurgia , Coelhos
8.
Int J Nanomedicine ; 12: 2933-2939, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28435269

RESUMO

BACKGROUND: Staphylococcus aureus biofilms contribute significantly to the recalcitrant nature of chronic rhinosinusitis. In previous studies, it has been shown that silk fibroin-nano silver solution can eliminate S. aureus biofilms in vitro, which suggests a potential role of this novel agent in the treatment of biofilm-associated diseases, such as sinusitis. OBJECTIVE: The aim of this study was to investigate the efficacy of silk fibroin-nano silver solution as a topical anti-biofilm agent in a rabbit model of sinusitis. METHODS: Biofilm-associated sinusitis models were established in 24 New Zealand White rabbits by gelatin sponge placement and S. aureus inoculation through a hole drilled into the anterolateral wall of the right maxillary sinus. After 4 weeks, indwelling catheters were placed into the maxillary sinus. Different concentrations of silk fibroin-nano silver solution or normal saline were irrigated slowly into the maxillary sinus via the indwelling catheters. After 7 days of irrigation, the rabbits were sacrificed. The sinus mucosa was harvested and examined for biofilm biomass as well as morphological integrity of the epithelium by scanning electron microscopy. RESULTS: Silk fibroin-nano silver solution was found to be most effective in reducing the biomass of the S. aureus biofilms at a concentration of 384 mg/L, followed by the concentration of 153.6 mg/L, when compared with saline. After treatment with 384 mg/L silk fibroin-nano silver solution, the biofilms were completely eliminated and the injured epithelium was almost restored with regenerated cilia on the surface. CONCLUSION: Silk fibroin-nano silver solution was found to be an effective topical agent against S. aureus biofilms in the rabbit model of sinusitis, and its effect was concentration-dependent.


Assuntos
Antibacterianos/farmacologia , Prata/farmacologia , Sinusite/tratamento farmacológico , Infecções Estafilocócicas/tratamento farmacológico , Administração Tópica , Animais , Antibacterianos/administração & dosagem , Antibacterianos/química , Biofilmes/efeitos dos fármacos , Cateteres de Demora , Doença Crônica , Fibroínas/química , Seio Maxilar/efeitos dos fármacos , Seio Maxilar/microbiologia , Seio Maxilar/patologia , Microscopia Eletrônica de Varredura , Nanocompostos/química , Coelhos , Prata/administração & dosagem , Prata/química , Sinusite/microbiologia , Infecções Estafilocócicas/microbiologia , Staphylococcus aureus/efeitos dos fármacos , Staphylococcus aureus/patogenicidade , Staphylococcus aureus/fisiologia
9.
Implant Dent ; 26(2): 178-186, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28301382

RESUMO

OBJECTIVE: Although increasing evidence has shown that long noncoding RNAs (lncRNAs) play an important regulatory role in pluripotency and differentiation of mesenchymal stem cells, little is known about the role of lncRNA in maxillary sinus membrane stem cells (MSMSCs). The goal of this study was to investigate the expression profile and function of lncRNAs on osteogenic differentiation of MSMSCs. MATERIALS AND METHODS: By using lncRNA microarray, we identify a novel osteogenesis differentiation-related lncRNA of MSMSCs (lncRNA-MODR). The functional role of lncRNA-MODR in regulating osteogenesis was evaluated by quantitative real-time polymerase chain reaction, western blot, and alizarin red staining. Bioinformatic analyses of the predicted target genes (gene ontology, pathway, and network analysis) were applied for further study of lncRNA-MODR. RESULTS: We show that lncRNA-MODR is gradually upregulated during osteogenic differentiation. lncRNA-MODR overexpression upregulated, whereas lncRNA-MODR silencing decreased the expression of the osteogenic key marker, runt-related transcription factor 2 (RUNX2). In-depth analyses showed that lncRNA-MODR acts as a molecular sponge for microRNA-454 (miR-454) and that prevents RUNX2 from mi-454-mediated suppression. CONCLUSION: The lncRNAs act as a competing endogenous RNA to sequester microRNA-454 (miR-454), leading to heightened RUNX2 expression and thus promotes osteogenesis of MSMSCs.


Assuntos
Seio Maxilar/efeitos dos fármacos , MicroRNAs/metabolismo , Osteogênese/fisiologia , RNA Longo não Codificante/metabolismo , Células-Tronco/efeitos dos fármacos , Western Blotting , Diferenciação Celular/efeitos dos fármacos , Subunidade alfa 1 de Fator de Ligação ao Core/metabolismo , Humanos , Seio Maxilar/citologia , Análise de Sequência com Séries de Oligonucleotídeos , Reação em Cadeia da Polimerase em Tempo Real , Células-Tronco/fisiologia
10.
Cell Physiol Biochem ; 40(5): 944-952, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27941347

RESUMO

BACKGROUND: Osteotome sinus floor elevation is a less invasive approach to augment an insufficient alveolar bone at the posterior maxilla for dental implantation. However, this approach has some limitations due to the lack of sinus lift tools available for clinical use and the small transcrestal access to the maxillary sinus floor. We recently invented shape-memory Ni/Ti alloy wire containing tube elevators for transcrestal detaching maxillary sinus mucosa, and developed goat ex vivo models for direct visualizing the effectiveness of detaching sinus mucosa in real time during transcrestal maxillary sinus floor elevation. METHODS: We evaluated our invented elevators, namely elevator 012 and elevator 014, for their effectiveness for transcrestal detaching maxillary sinus mucosa using the goat ex vivo models. We measured the length of sinus mucosa detached in mesial and distal directions or buccal and palatal directions, and the space volume created by detaching maxillary sinus mucosa in mesial, distal, buccal and palatal directions using the invented elevators. RESULTS: Elevator 012 had a shape-memory Ni/Ti alloy wire with a diameter of 0.012 inch, while elevator 014 had its shape-memory Ni/Ti alloy wire with a diameter of 0.014 inch. Elevator 012 could detach the goat maxillary sinus mucosa in the mesial or distal direction for 12.1±4.3 mm, while in the buccal or palatal direction for 12.5±6.7 mm. The elevator 014 could detach the goat maxillary sinus mucosa for 23.0±4.9 mm in the mesial or distal direction, and for 19.0±8.1 mm in the buccal or palatal direction. An average space volume of 1.7936±0.2079 ml was created after detaching the goat maxillay sinus mucosa in both mesial/distal direction and buccal/palatal direction using elevator 012; while the average space volume created using elevator 014 was 1.8764±0.2366 ml. CONCLUSION: Both two newly invented tube elevators could effectively detach the maxillary sinus mucosa on the goat ex vivo sinus models. Moreover, elevator 014 has advantages over the elevator 012 for the capability to detach sinus mucosa.


Assuntos
Seio Maxilar/efeitos dos fármacos , Mucosa/efeitos dos fármacos , Níquel/farmacologia , Levantamento do Assoalho do Seio Maxilar/métodos , Titânio/farmacologia , Animais , Estudos de Viabilidade , Feminino , Cabras , Masculino
11.
Curr Med Chem ; 23(24): 2736-2745, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27356533

RESUMO

Exhaled nitric oxide (NO) originates from the upper airways, and takes action, to varying extents, in regulation, protection and defense, as well as in noxious processes. Nitric oxide retains important functions in a wide range of physiological and pathophysiological processes of the human body, including vaso-regulation, antimicrobial activity, neurotransmission and respiration. This review article reports the ongoing investigations regarding the source, biology and relevance of NO within upper respiratory tract. In addition, we discuss the role of NO, originating from nasal and paranasal sinuses, in inflammatory disorders such as allergic rhinitis, sinusitis, primary ciliary dyskinesia, and cystic fibrosis.


Assuntos
Óxido Nítrico/metabolismo , Sistema Respiratório/metabolismo , Asma/diagnóstico , Asma/metabolismo , Humanos , Síndrome de Kartagener/diagnóstico , Síndrome de Kartagener/metabolismo , Seio Maxilar/efeitos dos fármacos , Seio Maxilar/metabolismo , Óxido Nítrico/análise , Doadores de Óxido Nítrico/farmacologia , Óxido Nítrico Sintase Tipo II/antagonistas & inibidores , Óxido Nítrico Sintase Tipo II/metabolismo , Sistema Respiratório/efeitos dos fármacos , Sinusite/diagnóstico , Sinusite/metabolismo
12.
In Vitro Cell Dev Biol Anim ; 52(7): 757-71, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27251156

RESUMO

Bone marrow-derived mesenchymal stem cells (BM-MSCs) have been recognized as a new strategy for maxillary sinus floor elevation. However, little is known concerning the effect of the biomechanical pressure (i.e., sinus pressure, masticatory pressure, and respiration) on the differentiation of BM-MSCs and the formation of new bone during maxillary sinus floor elevation. The differentiation of BM-MSCs into osteoblasts was examined in vitro under cyclic compressive pressure using the Flexcell® pressure system, and by immunohistochemical analysis, qRT-PCR, and Western blot. Micro-CT was used to detect bone formation and allow image reconstruction of the entire maxillary sinus floor elevation area. Differentiation of BM-MSCs into osteoblasts was significantly increased under cyclic compressive pressure. The formation of new bone was enhanced after implantation of the pressured complex of BM-MSCs and Bio-Oss during maxillary sinus floor elevation. The pressured complex of BM-MSCs and Bio-Oss promoted new bone formation and maturation in the rabbit maxillary sinus. Stem cell therapy combined with this tissue engineering technique could be effectively used in maxillary sinus elevation and bone regeneration.


Assuntos
Seio Maxilar/crescimento & desenvolvimento , Transplante de Células-Tronco Mesenquimais , Osteoblastos/citologia , Osteogênese , Animais , Células da Medula Óssea/citologia , Diferenciação Celular/genética , Humanos , Seio Maxilar/efeitos dos fármacos , Células-Tronco Mesenquimais , Minerais/administração & dosagem , Osteoblastos/efeitos dos fármacos , Coelhos , Levantamento do Assoalho do Seio Maxilar/métodos
13.
Bauru; s.n; 2016. 159 p. tab, ilus, graf.
Tese em Português | BBO - Odontologia | ID: biblio-881482

RESUMO

A técnica de levantamento de seio maxilar (LSM) visa aumentar a altura óssea junto à superfície sinusal de maxila posterior atrófica utilizando diferentes materiais de preenchimento, para possibilitar a instalação de implantes dentários. Esses materiais de preenchimento podem variar quanto à origem e às propriedades físicoquímicas, resultando em diferentes respostas biológicas. O objetivo do atual trabalho foi avaliar a eficiência do Gen-Ox®inorg e GenPhos XP® na técnica de elevação do seio maxilar em comparação ao Bio-Oss®. Em 24 coelhos foi realizado o levantamento bilateral dos seios maxilares (SMs) utilizando 200 mm3 de material de preenchimento por seio, conforme os grupos experimentais Bio-Oss (6SMs/período), Gen-Ox (5SMs/período) e GenPhos (5SMs/período), e a janela óssea de acesso foi recoberta com uma membrana reabsorvível. Os animais de cada grupo foram eutanasiados aos 15, 30 e 60 dias e a região dos SMs foi coletada e fixada em formalina a 10% tamponada. As peças foram submetidas à análise microtomográfica para determinação do volume total do SM elevado e em seguida ao processamento histológico, sendo cortes coronais dos SMs obtidos e avaliados morfometricamente pelo método de volumetria de pontos. Todos os três materiais apresentaram excelente biocompatibilidade e promoveram a manutenção do volume do seio preenchido ao longo do tempo, sendo em média de 214,1 mm3. Em todos os grupos a formação óssea ocorreu em íntimo contato com as partículas de material. Ao término de 60 dias, o tecido ósseo formado mostrava-se maduro e preenchia parcialmente os espaços entre as partículas. A forma e tamanho das partículas de Gen-Ox gerou maior espaço entre as partículas que pode ter levado a formação de maior volume de tecido ósseo e de tecido conjuntivo (53,0 ± 10,1 mm3 e 74,1 ± 21,5 mm3) comparado ao Bio-Oss (43,7 ± 11,6 mm3 e 61,2 ± 23,3 mm3) e GenPhos (47,5 ± 10,4 mm3 e 58,5 ± 25,7 mm3). Baseado na estabilidade do volume sinusal elevado, na capacidade osteocondutora e na formação e maturidade óssea ao longo do tempo promovidos pelo Gen-Ox®inorg e GenPhos®, comparável ao do Bio-Oss®, conclui-se que esses dois biomateriais significam uma alternativa segura na técnica de LSM.(AU)


Maxillary sinus augmentation (MSA) for implant placement using bone graft or bone substitutes is a common procedure to increase the bone volume in the atrophic posterior part of the maxilla. Various bone substitutes have been used in sinus floor elevation procedures. Nonetheless, the biological performance of bone substitutes may vary according to origin, physical and chemical properties. The goal of this study was to evaluate the efficiency of both Gen-Ox®inorg and GenPhos XP® in maxillary sinus augmentation technique compared to Bio-Oss®. In 24 rabbits, it was conducted a bilateral lifting of the maxillary sinuses (MSs) using 200 mm3 of filling material for sinus in accordance with the experimental groups Bio-Oss (6SMs/period), Gen-Ox (5MSs/period) and GenPhos (5MSs/period). The sinus access window was covered with a resorbable membrane. The animals of each group were euthanized at 15, 30 and 60 days and the MSs were collected and fixed in 10% buffered formalin. The samples were submitted to microtomographic analysis to calculate the MS augmentation volume. Histological coronal sections of MS augmentation were used for morphological analysis and determination of volume density of each structure by point counting volumetry method. All three materials had excellent biocompatibility and promoted maintenance of the MS augmentation volume over time, averaging 214.1 mm3. In all groups the bone formation occurred in close contact with the material particles. At the end of 60 days, the bone tissue formed was mature and it partially filled the spaces between the particles. The shape and size of Gen-Ox particles generated greater space between the particles that may have led to a higher formation of bone volume and connective tissue (53.0 ± 10.1 mm3 and 74.1 ± 21.5 mm3) than Bio-Oss (43.7 ± 11.6 mm3 and 61.2 ± 23.3 mm3) and GenPhos (47.5 ± 10.4 mm3 and 58.5 ± 25.7 mm3). Based on the stability of the MS volume, the osteoconductive capacity and the bone formation and maturation over time promoted by Gen-Ox®inorg and GenPhos®, and comparable to Bio-Oss®, it is concluded that these two biomaterials may be a safe alternative in MSA technique.(AU)


Assuntos
Animais , Masculino , Coelhos , Regeneração Óssea/efeitos dos fármacos , Substitutos Ósseos/uso terapêutico , Fosfatos de Cálcio/uso terapêutico , Cerâmica/uso terapêutico , Levantamento do Assoalho do Seio Maxilar/métodos , Regeneração Óssea/fisiologia , Seio Maxilar/efeitos dos fármacos , Seio Maxilar/patologia , Reprodutibilidade dos Testes , Resultado do Tratamento , Microtomografia por Raio-X/métodos
14.
J Clin Periodontol ; 42(1): 81-8, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25370371

RESUMO

AIM: The objective of study was to determine the osteogenic potential of bone morphogenetic protein-2 (BMP-2) loaded onto a particulate porcine bone mineral (PBM) biomaterial using a sinus augmentation model. METHODS: Release kinetics of BMP-2/PBM was determined in vitro. Eight rabbits received BMP-2/PBM or PBM alone into contra-lateral sinus sites. The animals were killed following a 2-week healing interval for micro-CT and histometrical analysis. RESULTS: Approximately 40% of the BMP-2 was released from PBM over the first 3 days in vitro; release maintained at a reduced level through day 21. In vivo, total augmented implant volume did not differ significantly between treatments. However, local bone formation was enhanced in the BMP-2/PBM group compared with PBM control (10.5% versus 6.6%; p = 0.03), specifically in the central aspect of the PBM implant (14.2% versus 5.5%; p < 0.01) and adjoining the Schneiderian membrane (11.9% versus 5.0%; p < 0.05). There were no significant overall differences in residual biomaterial and fibrovascular tissue. CONCLUSION: Bone morphogenetic protein-2 enhanced local bone formation in the rabbit maxillary sinus model following implantation using a PBM carrier.


Assuntos
Materiais Biocompatíveis/uso terapêutico , Proteína Morfogenética Óssea 2/uso terapêutico , Substitutos Ósseos/uso terapêutico , Osteogênese/efeitos dos fármacos , Levantamento do Assoalho do Seio Maxilar/métodos , Animais , Proteína Morfogenética Óssea 2/farmacocinética , Avaliação Pré-Clínica de Medicamentos , Células Gigantes/patologia , Processamento de Imagem Assistida por Computador/métodos , Imageamento Tridimensional/métodos , Masculino , Seio Maxilar/efeitos dos fármacos , Seio Maxilar/patologia , Mucosa Nasal/efeitos dos fármacos , Mucosa Nasal/patologia , Coelhos , Distribuição Aleatória , Suínos , Microtomografia por Raio-X/métodos
15.
Artigo em Chinês | MEDLINE | ID: mdl-25522571

RESUMO

OBJECTIVE: The aim of this study was to determine the expression of GATA-3 and the level of Th1 and Th2 cytokines upon repeated exposure to staphylococcal enterotoxin B(SEB) of different concentrations in the maxillary sinus mucosa of rabbits. METHOD: The rabbits were randomly divided into 2 groups (24 rabbits per group): low-dose SEB group and high-dose SEB group. The low-dose SEB group and high-dose SEB group received daily injections of 0.6 ng of SEB (2 ml) and 60 ng of SEB (2 ml) into the left maxillary sinus of rabbits for 28 days, respectively. Concurrent treatment of the right maxillary sinus with normal saline was used as a control. Six rabbits chosen randomly in two groups were killed on days 3, 7, 14, and 28, and to obtain the sinus mucosa from the two-side maxillary sinuses for measurement. Mucosal levels of IL-2, IL-4, IL-5, and IFN-γ were measured using ABC-ELISA. Tissue expression of GATA-3 were examined using Real-time PCR and immunohistochemistry. RESULT: IFN-γ and IL-2 levels were significantly elevated in the high-dose SEB group compared with the low-dose SEB and control groups on days 7, 14, and 28 (P < 0.05). However, IL-4 and IL-5 levels were markedly enhanced in the low-dose SEB group compared with the high-dose SEB and control groups on days 14 and 28 (P < 0.05). Real-time PCR showed that the expression of GATA-3 mRNA in the low-dose SEB group was markedly enhanced, and immunohistochemical staining illustrated that the number of GATA-3 positive cells was markedly increased in the low-dose SEB group as compared with the high-dose SEB group (P < 0.05). No significant differences were observed in GATA-3 expression between the high-dose SEB and the control groups (P > 0.05). CONCLUSION: SEB promoted Th1 cytokines production at high concentrations, and enhanced Th2 cytokines expression and Th2 immune response at low concentrations.


Assuntos
Citocinas/metabolismo , Enterotoxinas/farmacologia , Seio Maxilar/efeitos dos fármacos , Mucosa Nasal/metabolismo , Animais , Enterotoxinas/administração & dosagem , Ensaio de Imunoadsorção Enzimática , Interferon gama/metabolismo , Interleucina-2/metabolismo , Interleucina-4/metabolismo , Interleucina-5/metabolismo , Masculino , Seio Maxilar/metabolismo , RNA Mensageiro/metabolismo , Coelhos , Células Th1 , Células Th2 , Fatores de Transcrição/metabolismo
17.
J Craniomaxillofac Surg ; 42(6): 990-4, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24503388

RESUMO

Recently, several authors have shown that simultaneous sinus lift and implantation using autologous platelet-rich fibrin as the sole filling material is a reliable procedure promoting bone augmentation in the maxillary sinus. The aim of this study was to examine the effect of simultaneous sinus lift and implantation using platelet-rich fibrin as the sole grafting material on bone formation in a canine sinus model. An implant was placed after sinus membrane elevation in the maxillary sinus of six adult female mongrel dogs. The resulting space between the membrane and sinus floor was filled with autologous platelet-rich fibrin retrieved from each dog. The implants were left in place for six months. Bone tissue was seen at the lower part of the implants introduced into the sinus cavity. The height of the newly formed bone around the implants ranged from 0 mm to 4.9 mm (mean; 2.6 ± 2.0 mm) on the buccal side and from 0 mm to 4.2 mm (mean; 1.3 ± 1.8 mm) on the palatal side. The findings from this study suggest that simultaneous sinus lift and implantation using platelet-rich fibrin as sole grafting material is not a predictable and reproducible procedure, especially with respect to the bone formation around the implants in the sinus cavity.


Assuntos
Plaquetas/fisiologia , Implantação Dentária Endóssea/métodos , Fibrina/uso terapêutico , Levantamento do Assoalho do Seio Maxilar/métodos , Animais , Cães , Feminino , Géis , Maxila/efeitos dos fármacos , Seio Maxilar/efeitos dos fármacos , Modelos Animais , Osteogênese/efeitos dos fármacos , Plasma Rico em Plaquetas/fisiologia , Distribuição Aleatória , Retalhos Cirúrgicos/cirurgia , Fatores de Tempo , Cicatrização/fisiologia
18.
Artigo em Chinês | MEDLINE | ID: mdl-25623868

RESUMO

OBJECTIVE: To investigate the ultrastructure of ciliated epithelia and inflammatory changes upon repeated exposure to staphylococcal enterotoxin A (SEA) of different concentrations in the maxillary sinus mucosa of rabbits. METHODS: The rabbits were randomly divided into 2 groups (24 rabbits per group): low-dose SEA group and high-dose SEA group. The low-dose SEA group and high-dose SEA group received daily injections of 0.6 ng of SEA (2 ml) and 60 ng of SEA (2 ml) into the left maxillary sinus of rabbits for 28 days, respectively. Concurrent treatment of the right maxillary sinus with normal saline was used as control. Six rabbits chosen randomly in two groups were examined by computed tomography (CT) scans and then sacrificed to obtain the sinus mucosa from the two-side of maxillary sinuses for histological assessment on days 3, 7, 14 and 28. To characterize the inflammatory changes of the sinus mucosa examined using light microscope, hematoxylin and eosin (HE) and toluidine blue staining was performed. Scanning and transmission electron microscopy were performed to observe ultrastructure of ciliated epithelia in the maxillary sinus mucosa. SPSS 13.0 software was used to analyze the data. RESULTS: On days 14 and 28, CT images showed opacification of the left maxillary sinus in the high-dose SEA group. The percentage of epithelial disruption was (22.73 ± 5.72) % and (30.79 ± 4.30)% in the high-dose SEA group respectively, and were significantly greater than those in the low-dose SEA group (5.12% ± 1.98% and 5.38% ± 1.64%, q value was 10.079 and 19.132) and control group (4.08% ± 1.29% and 4.81% ± 1.62%, q value was 11.016 and 19.592, respectively, all P < 0.01). The subepithelial thickness in the high-dose SEA group was (113.34 ± 14.81)µm and (120.86 ± 12.35) µm respectively, and were significantly different from those of the low-dose SEA group [(71.08 ± 10.39)µm and (81.63 ± 9.32)µm, q value was 8.090 and 8.782] and control group [(37.45 ± 7.67)µm and (38.79 ± 7.68)µm, q value was 15.759 and 19.541, all P < 0.01]. Viewed under the electron microscope, loss of cilia was observed, a few compound cilia and cytoplasmic protrusion were found, an obvious stretching of the endoplasmic reticulum and an obvious turgescence of the mitochondria was also observed. However, in the low-dose SEA group on days 14 and 28, CT scan of the left maxillary sinus showed transparency; light microscopy observations of the maxillary sinus mucosa showed the number of eosinophils was markedly increased as compared with the high-dose SEA and control groups, the differences were significant (q value was 5.871 and 6.766 on day 14, and q value was 7.572 and 8.970 on day 28, respectively, all P < 0.05). But no significant differences were observed in epithelial disruption between the low-dose SEA and the control groups on days 14 and 28 (q value was 1.512 and 0.859 respectively, all P > 0.05); inordinate array and adhesion of cilia was observed, but cilia loss, compound cilia, cytoplasmic protrusions, mitochondrial swelling and endoplasmic reticulum stretching were not found. CONCLUSIONS: SEA may induce allergic inflammation of the sinus mucosa without damaging the structure of ciliated epithelia at low concentration. Whereas SEA impairs the structure of mitochondria and endoplasmic reticulum in ciliated epithelial cells at high concentration, and results in cilia loss and epithelial disruption, which may be one of the main reasons to induce acute sinusitis.


Assuntos
Cílios/ultraestrutura , Enterotoxinas/toxicidade , Células Epiteliais/ultraestrutura , Seio Maxilar/ultraestrutura , Animais , Cílios/efeitos dos fármacos , Cílios/fisiologia , Efeitos Psicossociais da Doença , Eosinófilos , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/fisiologia , Contagem de Leucócitos , Seio Maxilar/efeitos dos fármacos , Seio Maxilar/metabolismo , Mucosa/efeitos dos fármacos , Mucosa/fisiologia , Mucosa/ultraestrutura , Coelhos , Sinusite
19.
Head Neck ; 35(10): E321-4, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23047661

RESUMO

BACKGROUND: Immunoglobulin G4 (IgG4)-related sclerosing disease is a systemic disease characterized by extensive IgG4-positive plasma cells and T-lymphocyte infiltration of various organs. We present a case of a 69-year-old man with maxillary sinus IgG4 sclerosing disease, with orbital invasion treated with rituximab and dexamethasone pulse therapy. Surgery was used as well to debulk the disease and to obtain tissue for diagnosis. METHODS: A PubMed search using the key phrase "IgG4-related Sclerosing Disease" was performed. There were 304 different articles regarding the disease for a multitude of different organ sites. Of the 304 articles, there were 3 articles that reported this disease in the paranasal sinuses. CONCLUSIONS: IgG4-related sclerosing disease is a rare entity in the head and neck. There are documented reports of steroid therapy for this disease, but the patient presented here demonstrated clinical progression of disease with steroids alone. The use of combination therapy of surgery, dexamethasone, and rituximab provided clinical improvement and stable disease determined by radiographic means.


Assuntos
Imunoglobulina G/imunologia , Seio Maxilar/patologia , Doenças Orbitárias/patologia , Doenças Orbitárias/cirurgia , Doenças dos Seios Paranasais/patologia , Doenças dos Seios Paranasais/terapia , Idoso , Anticorpos Monoclonais Murinos/administração & dosagem , Biópsia por Agulha , Doença Crônica , Terapia Combinada , Descompressão Cirúrgica/métodos , Dexametasona/administração & dosagem , Seguimentos , Humanos , Imuno-Histoquímica , Imageamento por Ressonância Magnética/métodos , Masculino , Seio Maxilar/efeitos dos fármacos , Seio Maxilar/cirurgia , Doenças Orbitárias/imunologia , Doenças dos Seios Paranasais/imunologia , Rituximab , Esclerose , Índice de Gravidade de Doença , Sinusite/diagnóstico , Sinusite/etiologia , Tomografia Computadorizada por Raios X/métodos , Resultado do Tratamento
20.
Br J Oral Maxillofac Surg ; 51(3): 247-52, 2013 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22766268

RESUMO

The aim of this study was to evaluate the quantity and quality of bony regeneration after we had used recombinant human bone morphogenetic protein-7 (rhBMP-7 to augment the floor of the maxillary sinus. Nine consecutive patients with bilateral posterior maxillary atrophy who required augmentation of the sinus for interposition of implants were treated simultaneously with rhBMP-7 (Osigraft) with deproteinised bone substitute (0.5 g on the test side) and with deproteinised bone alone (2.0 g on the control side). Computed tomographic images preoperatively, immediately postoperatively, and at 4 months postoperatively showed a mean (SD) postoperative gain of 10.8 (3.0) mm on the test side and of 10.2 (1.8) mm on the control side. Histological and histomorphometric analyses of biopsy specimens showed that there was significantly more new bone on the control side (19.9 (6.8)%) than on the test side (6.6 (4.8)%). In this pilot controlled trial of the use of rhBMP-7, histological analyses showed that it resulted in the formation of less bone than treatment with inorganic bovine hydroxyapatite.


Assuntos
Proteína Morfogenética Óssea 7/uso terapêutico , Levantamento do Assoalho do Seio Maxilar/métodos , Implantes Absorvíveis , Adulto , Atrofia , Densidade Óssea/fisiologia , Regeneração Óssea/efeitos dos fármacos , Substitutos Ósseos/uso terapêutico , Transplante Ósseo/métodos , Colágeno , Implantes Dentários , Durapatita/uso terapêutico , Feminino , Seguimentos , Humanos , Masculino , Maxila/patologia , Seio Maxilar/efeitos dos fármacos , Seio Maxilar/patologia , Membranas Artificiais , Pessoa de Meia-Idade , Minerais/uso terapêutico , Osseointegração/efeitos dos fármacos , Osteogênese/efeitos dos fármacos , Piezocirurgia/métodos , Projetos Piloto , Estudos Prospectivos , Tomografia Computadorizada por Raios X/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...